#China #Shanghai #ADC #Mabwell #7MW4911

Mabwell Advances Cancer Treatment with First Patient Dosed

Mabwell, an innovation-driven biopharmaceutical company based in Shanghai, has recently taken a significant step in the fight against cancer. On November 25, 2025, the company announced that the first patient has been dosed in its Phase I/II clinical trial for 7MW4911, a novel antibody-drug conjugate (ADC) specifically targeting CDH17. This groundbreaking trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of 7MW4911 in individuals with advanced solid tumors.

Importance of the Trial

The clinical trial, registered under CTR20254163, represents a crucial milestone for Mabwell, as it seeks to develop effective treatments for patients battling advanced colorectal cancer and other gastrointestinal tumors. The FDA previously granted investigational new drug (IND) clearance for this clinical trial under the NCT07216560 registry, allowing Mabwell to advance its pioneering research efforts.

The 7MW4911 ADC

7MW4911 stands out in its class due to its unique design. It leverages Mabwell's proprietary IDDC™ platform, incorporating a highly specific CDH17 monoclonal antibody. This antibody is adept at efficiently internalizing into tumor cells, enhancing the ADC's effectiveness. Additionally, it utilizes a novel cleavable linker known for its high plasma stability, coupled with a proprietary DNA topoisomerase I inhibitor payload named MF-6. This design particularly addresses the challenge of multidrug resistance, which is a common hurdle in cancer therapies.

Preclinical studies of 7MW4911 have shown promising results, demonstrating potent antitumor activity across patient-derived xenograft (PDX) models of various gastrointestinal tumors. Interestingly, in models exhibiting multidrug resistance, 7MW4911 outperformed established MMAE/DXd-based ADCs and was notable for its ability to reverse tumor progression, showcasing its potential as a preferred option for patients facing resistant tumors. These findings were highlighted in recent publications at the 2025 AACR conference and in the esteemed journal Cell Reports Medicine in July 2025.

Mabwell's Vision

Mabwell's commitment to innovation in biopharmaceutical development reflects its mission: "Explore Life, Benefit Health." With a comprehensive approach spanning the entire pharmaceutical value chain, the company aims to deliver more effective and accessible therapies to address global medical needs, specifically in oncology and age-related diseases.

Future Prospects

The initiation of this clinical trial marks only the beginning of Mabwell's journey with 7MW4911. The company faces numerous challenges typical of biopharmaceutical development, including navigating regulatory hurdles and ensuring the success of ongoing clinical studies. However, the enthusiasm surrounding the potential of 7MW4911 continues to grow within the medical community, offering hope to patients affected by advanced solid tumors.

For more information, visit Mabwell's official website.

As Mabwell progresses in this innovative research, the biopharmaceutical landscape is closely watching, hopeful for new advancements that could redefine treatment paradigms in cancer care.